Nestoras Mathioudakis, MD MHS

I’m excited to announce the publication of our article in Clinical Diabetes, detailing a transformative state-wide initiative aimed at enhancing participation in the Diabetes Prevention Program ( ) and Diabetes Self-Management Education and Support ( ) services.

This 4-year initiative (2021-2024), funded by the Maryland Health Services Cost Review Commission (HSCRC), was a collaborative effort between Johns Hopkins Medicine and the University of Maryland Medical System, known as the Baltimore Metropolitan Diabetes Regional Partnership. In just the first year of the program, we saw significant increases in referrals and participation thanks to targeted investments and innovative quality improvement strategies!

It's important to note that participation in these evidence-based programs remains low across the U.S., not just in Maryland. We hope this initiative serves as a valuable playbook for other health systems and public health departments looking to expand vital services for individuals with and .

Scaling the Diabetes Prevention Program and Diabetes Self-Management Education and Support Services Across a Health System This article describes and evaluates a multipronged strategy to expand use of the Diabetes Prevention Program (DPP) and diabetes self-management education

Excited to share findings from our recent study on the use of dexamethasone for COVID-19 in people with diabetes. Unlike in other hospitalized patients, we found that dexamethasone did not improve survival or recovery time for patients with diabetes. However, there was no higher risk of dangerous spikes in blood sugar levels.

For patients with more severe COVID-19 and diabetes, we actually saw slower recovery with dexamethasone, indicating the need for more research in this area.

Effectiveness of Dexamethasone for COVID-19 in Hospitalized Patients With Diabetes: A Retrospective Cohort Study AbstractBackground. Patients with diabetes have higher mortality from COVID-19 compared to the general population. Dexamethasone, a potent glucocorticoid u

🚀 Exciting News! 🚀

We've just published our clinical trial protocol comparing an AI-powered digital Diabetes Prevention Program ( ) with the standard human coach-based DPP. This study aims to see if artificial intelligence can provide a scalable, cost-effective way to combat prediabetes, a problem that affects more than 1 in 3 U.S. adults.

Enrollment of 368 participants complete, and results are expected in early 2025. Stay tuned for more updates!

Read more here: https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-024-08177-8

JJHM Diabetes Prevention & Education ProgramJJohns Hopkins Brancati CenterRReading Hospital - Tower Health

Effectiveness of artificial intelligence vs. human coaching in diabetes prevention: a study protocol for a randomized controlled trial - Trials Background Prediabetes is a highly prevalent condition that heralds an increased risk of progression to type 2 diabetes, along with associated microvascular and macrovascular complications. The Diabetes Prevention Program (DPP) is an established effective intervention for diabetes prevention. Howeve...

Episode 30: Prediabetes - The Johns Hopkins Patient Guide to Diabetes Episode 30: Prediabetes Print PDF Home | Podcast | Episode 30: Prediabetes On today’s podcast, Dr. Kalyani welcomes Dr. Nes Mathioudakis, who will be speaking with us about prediabetes. Dr. Mathioudakis is an endocrinologist at Johns Hopkins focusing his clinical practice on the care of patients w...